Where this fund manager is looking to catch the investment waves in 2026
Forager Funds
January 15, 2026
Wide market dispersion, shifting sentiment, and unloved sectors may shape
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
Wide market dispersion, shifting sentiment, and unloved sectors may shape
The CSL Ltd (ASX:CSL) share price is in focus after
The CSL Ltd (ASX:CSL) share price is down more than
The CSL Ltd (ASX:CSL) share price dropped around 3% as
The CSL Ltd (ASX:CSL) share price is in focus after
In this episode of the Australian Investors Podcast, discover the
Discover why gold is surging, whether Google remains undervalued, and
The Australian Investors Podcast: Drew Meredith and Owen Rask cover
The CSL Ltd (ASX: CSL) share price is down 16%
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.